Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
29 févr. 2024 16h05 HE
|
Sana Biotechnology, Inc
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in...
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
28 févr. 2024 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
13 févr. 2024 16h05 HE
|
Sana Biotechnology, Inc
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence...
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12 févr. 2024 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
Sana Biotechnology Announces Pricing of Upsized Public Offering
08 févr. 2024 01h22 HE
|
Sana Biotechnology, Inc
SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
Sana Biotechnology Announces Proposed Public Offering of Common Stock
07 févr. 2024 16h01 HE
|
Sana Biotechnology, Inc
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
05 janv. 2024 09h00 HE
|
Sana Biotechnology, Inc
SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food...
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
11 déc. 2023 09h00 HE
|
Sana Biotechnology, Inc
Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission Validation of novel and fully-human GPRC5D-specific CARs for the development...
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
01 déc. 2023 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication...